ImmunoPrecise Antibodies (OTCMKTS:IPATF) versus Mettler-Toledo International (NYSE:MTD) Financial Analysis

Mettler-Toledo International (NYSE:MTD) and ImmunoPrecise Antibodies (OTCMKTS:IPATF) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Valuation and Earnings

This table compares Mettler-Toledo International and ImmunoPrecise Antibodies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.03 billion	7.07	$869.19 million	$44.43	31.97
ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A

Mettler-Toledo International has higher revenue and earnings than ImmunoPrecise Antibodies.

Profitability

This table compares Mettler-Toledo International and ImmunoPrecise Antibodies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
ImmunoPrecise Antibodies	N/A	N/A	N/A

Institutional and Insider Ownership

95.1% of Mettler-Toledo International shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Mettler-Toledo International and ImmunoPrecise Antibodies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	0	7	6	0	2.46
ImmunoPrecise Antibodies	0	0	0	0	0.00

Mettler-Toledo International presently has a consensus target price of $1,461.27, indicating a potential upside of 2.88%. Given Mettler-Toledo International’s stronger consensus rating and higher probable upside, research analysts plainly believe Mettler-Toledo International is more favorable than ImmunoPrecise Antibodies.

Summary

Mettler-Toledo International beats ImmunoPrecise Antibodies on 8 of the 9 factors compared between the two stocks.

About Mettler-Toledo International

Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company’s laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company’s retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd. engages in the provision of human therapeutic antibody discovery and development services. It offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.